Nexalin Technology (NASDAQ:NXL) Stock Rating Upgraded by Wall Street Zen

Nexalin Technology (NASDAQ:NXL) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Nexalin Technology in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $5.00.

Nexalin Technology Price Performance

NXL opened at $1.50 on Friday. The firm has a fifty day moving average price of $1.11 and a 200 day moving average price of $1.15. Nexalin Technology has a 1 year low of $0.70 and a 1 year high of $4.49. The stock has a market cap of $26.48 million, a P/E ratio of -1.97 and a beta of 3.62.

Nexalin Technology (NASDAQ:NXL) last posted its earnings results on Wednesday, August 6th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.04. Nexalin Technology had a negative net margin of 5,057.14% and a negative return on equity of 209.20%. The firm had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.04 million.

About Nexalin Technology

Nexalin Technology, Inc, a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia.